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Abstract
Background: There has been considerable growth in basic knowledge and understanding of how genes are
influencing response to exercise training and predisposition to injuries and chronic diseases. On the basis of this
knowledge, clinical genetic tests may in the future allow the personalisation and optimisation of physical activity,
thus providing an avenue for increased efficiency of exercise prescription for health and disease.
Results: This review provides an overview of the current status of genetic testing for the purposes of exercise
prescription and injury prevention. As such there are a variety of potential uses for genetic testing, including
identification of risks associated with participation in sport and understanding individual response to particular
types of exercise. However, there are many challenges remaining before genetic testing has evidence-based
practical applications; including adoption of international standards for genomics research, as well as resistance
against the agendas driven by direct-to-consumer genetic testing companies. Here we propose a way forward to
develop an evidence-based approach to support genetic testing for exercise prescription and injury prevention.
Conclusion: Based on current knowledge, there is no current clinical application for genetic testing in the area of
exercise prescription and injury prevention, however the necessary steps are outlined for the development of
evidence-based clinical applications involving genetic testing.
Background
Physical inactivity accounts for approximately 6% of the
worldwide burden of disease and globally, around 23%
of adults aged 18 years and over did not meet physical
activity guidelines in 2010 [1]. Physical inactivity in-
creases the risk of developing a range of conditions in-
cluding hypertension, coronary heart disease, stroke,
diabetes, breast and colon cancer; while physical activity
is a key determinant of energy expenditure, and funda-
mental to energy balance and weight control [1]. En-
gaging in physical activity on a regular basis (e.g.,
exercise training) is therefore crucial for increasing car-
diorespiratory fitness and decreasing the risk for chronic
diseases. Physical activity levels and the response to
similar exercise training vary considerably, with some
people being ‘low/medium responders’ (with limited im-
provements following exercise training), while others re-
spond well or very well (‘high responders’) [2]. This
variable response appears to be influenced by both envir-
onmental (e.g. training status, nutrition, social economic
status) and genetic factors.
While there have been some advances in knowledge
and understanding of how genes are influencing the re-
sponse to exercise training and predisposition to injuries
and chronic diseases, the development of genetic tests
which allow the personalisation and optimisation of
physical activity remains elusive [3]. In the future, such
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tests may provide an avenue for increased efficiency of
exercise prescription and injury prevention. Addition-
ally, there are a range of genetic conditions that may
impede an individual’s participation in exercise, with
the most severe of these leading to an increased risk of
sudden cardiac death [4, 5]. In particular, genes associ-
ated with cardiomyopathies may be of interest to sports
medicine physicians [5]. Discovering genes that are as-
sociated with the predisposition of the severest of com-
mon sports injuries has become a particular focus of
research interest.
Minimising time loss from injury has been correlated
with athletic success for both teams and individuals [6, 7].
Additionally, sports injuries in recreational athletes have
significant public health impact and consequences for fu-
ture participation in sport and recreational activities [8].
Comprehensive injury surveillance is performed by many
professional sporting bodies to examine the impact of par-
ticular injuries. The international bodies such as the Inter-
national Olympic Committee (IOC) and the Fédération
Internationale de Football Association (FIFA) systematic-
ally survey injuries in their major events [9–12]. For ex-
ample, analysis of the London Olympic Games found
that 11% of athletes reported an injury during the
Games [12]. Prevention of injury in the sports arena is
a high priority for athletes, coaches, high performance
staff and medical personnel. Consequently, there has
been significant research in the area of genetic variation
and its impact on susceptibility to exercise-related in-
juries, with a particular focus on tendon and ligament
injuries [13]. Much of this research is aimed at deter-
mining an individual’s susceptibility to, and/or risk of
acquiring a sport injury and implementing preventative
strategies.
The rapid development of genetic and genomic tech-
niques has led to an increase in interest in the genetics
of physical activity and sport. The Athlome Project Con-
sortium was established in 2015 to collectively study the
limited genotype and phenotype data available in elite
athletes, as well as focusing on adaptation to exercise
training and exercise-related musculoskeletal injuries
[14]. The ultimate goal of this consortium is to inform
personalised training and injury prevention, as well as
informing doping detection utilising collaborative and
rigorous research. Often studies within the field of exer-
cise/injury genomics are limited by cohort sizes and
other methodological concerns. The Athlome consor-
tium has recently advocated an approach to overcome
the main gaps in this research field [14], and to serve as
a collective guiding reference in the identification of reli-
able genetic tests for exercise training and sports injur-
ies. This review provides a statement on the state of play
in genetic testing for the purposes of exercise prescrip-
tion and injury prevention.
Potential uses of genetic testing for exercise and
health
Identifying those who are at increased risk (or resilient) to
musculoskeletal injury
Participation in sport or exercise training can lead to
acute and chronic musculoskeletal injuries. For athletes,
time lost from training and competition due to injury
has a profoundly negative impact on performance. Add-
itionally, when a member of the public who is engaged
in exercise training acquires an injury this can lead to a
lack of motivation towards, or fear of returning to train-
ing [15]. Several factors, both intrinsic and extrinsic, are
reported to predispose an individual to musculoskeletal
injury, including demographic factors (e.g., sex, age,
weight, and height), anatomical factors (e.g., leg length
discrepancy, malalignment and decreased flexibility), and
environmental conditions (e.g., training patterns, tech-
nique flaws and equipment) [16–19]. Genetic variations
also play a role in the risk profile for musculoskeletal in-
jury [13].
Identification of gene variations that may lead to an
increased or decreased risk of sport/exercise injury has
been studied for a range of conditions including liga-
ment [20–23], tendon [22, 24–27], muscle [28, 29], and
bone injuries [30, 31]. Primarily this has been done using
the hypothesis-driven, candidate gene approach, where a
case-control cohort is examined for genetic variation in
genes of interest and the occurrence of musculoskeletal
injuries, focusing on genes involved in the extracellular
matrix and apoptosis pathways (e.g., [13]). To date there
has been only one genome-wide association study
(GWAS) published in the area of sports injury, which
did not identify any significant gene variations contribut-
ing to Achilles tendon or ACL injury [32]. The sample
sizes of the candidate gene studies have been quite small
(typically between 100 and 200 cases) [33]. In contrast,
GWAS have utilised tens to hundreds of thousands of
individuals to identify genetic variants in migraine and
Alzheimer’s disease [34, 35]. It has been acknowledged
that further investigation with appropriately sized co-
horts is required to replicate and correctly interpret the
association of identified polymorphisms with specific in-
juries [33]. Such studies should also be repeated in other
populations, including non-Caucasian populations [26].
Importantly, gene-discovery studies should be accom-
panied by functional studies that would demonstrate, in
either animal or human models, how newly identified
gene variations could cause molecular/cellular changes
leading to increased/decreased susceptibility to an
injury.
There is future potential to use genetic screening in
assessing risk of musculoskeletal injuries, providing an
avenue to modify training, conditioning programs and
physical therapy intervention in order to prevent
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injuries. The current level of evidence however does not
support the clinical use of genetic screening. Further re-
search is required to gain a deeper understanding of the
range of gene variants that contribute to risk of injury
and the effectiveness of personalised training regimens
in reducing injury incidence when compared to usual
training.
Identifying high/low responders to specific training
protocols in healthy and diseased populations
Specific training protocols assist athletes, or exercise
participants, in achieving fitness goals. Tailoring exercise
programs to fit the specific needs of athletes and/or the
general population may provide an efficient mechanism
for rapid development of aerobic fitness and strength.
From the response to exercise training literature, it has
become clear that there is considerable individual vari-
ability in the response to similar exercise training [36].
The implications are that some individuals are ‘low re-
sponders’ (improving their fitness only slightly following
a specific exercise training) while others respond well or
very well (‘high responders’). Response to training also
seems to depend on the type and length of the exercise
training protocol. For example, intense intermittent exer-
cise, or interval training, has gained popularity in the last
few years and is a powerful stimulus to induce many of
the physiological adaptations typically associated with
traditional, moderate-intensity continuous training [37].
However, not everyone responds similarly to this type of
training, and it would appear that genetic variants play an
important role in this variable response [2]. Uncovering
the genes behind the individual response to exercise train-
ing therefore has exciting implications for “personal medi-
cine” and the development of individualised exercise
training and health programs. This development could
have important health and economic ramifications by en-
suring that specific types of exercise interventions are
prioritised to those most likely to attain the greatest
benefit.
Several types of chronic diseases, including cancer,
have been shown to benefit from generalised physical ac-
tivity, such as walking, or exercise training [38–42]. Ex-
amples of the application of different training types have
shown that some chronic conditions are better suited to
a particular type of training. Studies have shown that re-
sistance training can improve cognitive function in pa-
tients with mild cognitive impairment, and can increase
muscle strength and fat-free mass in frail elderly patients
with sarcopenia [43, 44]. Other studies have shown po-
tential benefits to using either endurance or resistance
training in chronic obstructive pulmonary disease, or
that exercise and generalised physical activity is benefi-
cial to those undergoing cancer treatment [45, 46].
The application of genomic techniques to develop
individual exercise prescription based on the type of
disease and the patient’s predicted response to exer-
cise would assist in targeting treatment; so-called per-
sonalised medicine. While there is a great deal of
research being undertaken to identify genetic predic-
tors of response or non-response to specific exercise
regimes, there are currently no valid genetic tests that
can be clinically applied for this purpose.
Identifying those who may have uncommon disorders
and be at specific risk in sport
Some genetic disorders do confer a significant health
risk for individuals undertaking strenuous activity. Sud-
den cardiac death is the leading medical cause of death
in athletes, with variable incidence rate in athlete sub-
groups, with the highest risk being reported in male
African-American/black athletes and basketball players
[47]. Several gene variants have been shown to be associ-
ated with cardiac electrophysiology, arrhythmias, and
sudden cardiac death, however very few of these studies
have been replicated and functional implications of the
genes are not always clear [4]. There is therefore a press-
ing need to conduct research that could enable the risk
of sudden cardiac death for each individual to be estab-
lished and determine if the characteristics of a particular
sport increases that risk [48]. Athletes with diagnosed
heart conditions, such as hypertrophic cardiomyopathy,
may be advised against participation in competitive
sports and discouraged from intense physical activity,
dependent on the severity of their condition [49].
Marfan syndrome is an inherited connective tissue dis-
order associated with ocular, musculoskeletal and car-
diovascular manifestations, characterised by a tall and
slender build and disproportionately long limbs, posing
potential lethal threat during high-intensity exercise
[50]. Marfan syndrome has an incidence of 4–20/
100,000 depending on the population studied and diag-
nostic criteria used [51]. Marfan syndrome results most
commonly from mutations in the fibrillin-1 gene on
chromosome 15, which encodes for the glycoprotein
fibrillin [52]. Where a family history, symptom history,
physical examination or diagnostic investigations (slit
lamp ocular examination, echocardiogram) raise suspicion
of Marfan syndrome, molecular studies of the fibrillin
gene may be useful in clarifying the diagnosis. Marfan syn-
drome is one condition that disproportionately affects ath-
letes in sports where height provides a distinct advantage
due to the athletic phenotype caused by genetic muta-
tions. Sudden death by aortic aneurysm and dissections
represent the most serious clinical manifestation of this
disease, and as such, sporting organisations where a tall
slender build with long limbs is advantageous (such as vol-
leyball and basketball) may see the need to mitigate this
risk by using screening of athletes.
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Conducting a clinical evaluation should always be the
first step before performing a genetic test. Genetic test-
ing is especially indicated in the following scenarios;
positive family history of inherited heart disease (e.g.,
cardiomyopathies, channelopathies, aortopathies) or sus-
picion of that type of disease (e.g., syncope episodes, ar-
rhythmias, cardiac arrest, sudden death); or when the
athlete’s phenotype strongly indicates the presence of an
inherited disease (Marfan syndrome) [49]. Sporting orga-
nisations wishing to conduct genetic investigations into
conditions that may lead to increased risk of sudden car-
diac death should engage a medical practitioner to ensure
that appropriate clinical examination and counselling
takes place prior to conducting genetic testing.
Challenges for genetic testing in sport and
exercise medicine
Cohort size
One of the major limitations in the field of exercise/in-
jury genomics is the relatively low sample size of sub-
jects and/or the general population participating in
exercise training studies. Major collaborative effort is re-
quired for the field to progess, and enhance our under-
standing of the genes that influence the response to
exercise and predisposition to injury. Improving cohort
numbers in current biobanks would pave the way for
genome-wide testing. To date, the analysis of single vari-
ant candidate genes (often poorly justified) using low-
throughput techniques has yielded conflicting findings
and inconsistent results. Current GWAS and Whole-
Genome Sequencing (WGS) technology means that mil-
lions of gene variants are analyzed per individual [53]. A
recent study utilised 375,000 individuals to identify 38
loci related to susceptibility of migraine [35]. A similar
style of genome-wide approach, designed with sufficient
power could identify specific regions or variants that
contribute to increased/decreased susceptibility to injur-
ies and the response to exercise training.
As a result of the rapid advances in the development
and uptake of high-throughput DNA-sequencing
methods, progress is now being made in understanding
the genetic basis of rare, and also some of the common
diseases [54]. The first attempt to utilise a GWAS ap-
proach for athletic performance was recently undertaken
by an international consortium (GAMES) [55]. This
GWAS involved two cohorts of elite endurance athletes
and controls (GENATHLETE and Japanese endurance
runners), from which a panel of 45 promising markers
was identified. These markers were tested for replication
in seven additional cohorts of endurance athletes and
controls: from Australia, Ethiopia, Japan, Kenya, Poland,
Russia and Spain. This first of a kind study was based on
a total of 1520 endurance athletes (835 who took part in
endurance events in World Championships and/or
Olympic Games) and 2760 controls. Although this inves-
tigation did not identify a panel of genomic variants
common to these elite endurance athlete groups, some
of the suggestive leads identified warrant further investi-
gation in expanded comparisons of world-class endur-
ance athletes and sedentary controls and in tightly
controlled exercise training studies [55].
In a recent, more successful effort to discover the genes
associated with muscle strength, Willems et al. [56] exam-
ined the genetic loci associated with hand grip strength,
which is a marker of muscular fitness and frailty, with
lower hand grip strength associated with lower quality of
life. Results were obtained from a combined sample of
195,180 individuals, initially utilising a UK DNA Bio-
bank, with follow up analysis in independent samples
of elite sprinters. The significant cohort size lead to
identification of 16 loci associated with grip strength
(P < 5 × 10−8) in combined analyses. A number of these
loci contain genes implicated in structure and function
of skeletal muscle fibres (ACTG1), neuronal mainten-
ance and signal transduction (PEX14, TGFA, SYT1), or
monogenic syndromes with involvement of psycho-
motor impairment (PEX14, LRPPRC and KANSL1). Im-
portantly, this recent discovery provides new biological
insight into the mechanistic underpinnings of muscle
strength.
Cohort homogeneity
Another limitation common to the field of exercise/in-
jury genomics is the cohort homogeneity. The majority
of studies in sport and exercise genetics have been con-
ducted using Caucasian/European subjects. While the
homogeneity of the cohort assists in discovery of poten-
tial gene variants of significance, this poses a problem
for the application of genetic tests to the broader com-
munity. Although we predict that the development of as-
sessment tools will benefit from individual genomic
information, not all of these applications may be extrap-
olated from the Caucasian cohorts to other populations.
Encouragingly, there have been some recent attempts to
study the genome of Asian (i.e., Chinese, Japanese, Tai-
wanese) and South American (i.e., Brazilian) athletes
[57–59]. This trend is increasingly growing with the use
of collaborative approaches and data sharing between
international research centers.
An additional consideration in cohort homogeneity
is the gene-by-sex interactions. Exercise genomic
studies primarily utilise mixed cohorts of males and
females, and account for sex differences as a covariate
in their statistical analyses. For example, compelling
findings of sex-dependent genetic effects on disease
have been reported in type II diabetes [60] and autism
spectrum disorders [61], which further complicates
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the issue of pooling together females and males into
one cohort.
Growth of DTC companies promoting non-evidence based
testing
There has been a rapid expansion of direct-to-consumer
(DTC) genetic testing services, with those services being
provided to members of the public on a commercial basis
without any involvement of a medical practitioner [62]. A
range of companies offer DTC genetic testing, purporting
to examine how one’s genes contribute to their athletic
prowess. DTC companies commonly offer advice in terms
of trainability or personalised training programs, predis-
position to athletic success in power/endurance sports,
and advice relating to weight loss management [62], des-
pite the lack of evidence to support such advice. This type
of DTC marketing targets athletes, parents, coaches and
people from the general population seeking an athletic
‘edge’, and altered response to exercise training for success
in sporting performance.
There are numerous problems inherent with the
provision of advice based on the current repertoire of
DTC genetic tests. In 2006, the United States Govern-
ment Accountability Office (GAO) investigated compan-
ies selling DTC genetic tests and testified that these
companies made medically unproven disease predictions
[63]. For example, samples sent from the one individual
to different DTC genetic companies resulted in incon-
sistent reporting between companies, including conflict-
ing risk predictions for a range of diseases [63]. A
systematic review of DTC genetic tests concluded that it
is unacceptable that online companies offer genetic test-
ing lacking scientific evidence and having no proven
clinical utility, and make misleading marketing claims
[64]. Recent research also suggests that DTC genetic
testing companies massively exaggerate the predictive
powers of their tests by distorting scientific evidence to
support unfounded claims and in doing so have eroded
the faith in the science behind genetic testing [65]. In re-
sponse to this situation, a number of countries have in-
stigated legislation to ensure that genetic testing cannot
be carried out without the involvement of a medical
practitioner, while there is no such legislated protection
for consumers in certain other countries [66–68]. How-
ever, the DTC tests that draw conclusions about sporting
performance do not provide health advice to the con-
sumer and, therefore, may not meet the criteria to be
regulated under current legislation.
A joint FIMS-Athlome Consensus Statement in 2015
warned against the use of DTC tests in athletes, stating
that the current level of genetic knowledge is being mis-
represented implicitly for commercial purposes and con-
cluding that there is no place for DTC testing for
predicting sports performance and talent identification [62].
Recently, the Australian Institute of Sport (AIS) has also de-
veloped a position statement to address the implications of
recent advances in the field of genetics and the ramifica-
tions for the health and well-being of athletes [69].
Potential ethical dilemmas
Numerous ethical dilemmas exist in relation to genetic
testing, for purposes other than medicine. Genomic test-
ing raises a number of important issues for those pre-
scribing the test, including the complexity of informed
consent, sample and data storage, return of results, testing
involving children, and privacy and confidentiality [70].
The AIS detailed their position in relation to the ethical
dilemmas facing genetic and genomic testing of athletes
[69]. In brief, genomic and genetic testing for non-medical
purposes must be well thought out, with clear and trans-
parent planning for all aspects of information manage-
ment outlined prior to the commencement of testing. The
right of refusal for non-participation must be respected
and there should be no discrimination against athletes
based on their participation in testing or the results
attained from a genetic or genomic test. A clear process,
involving genetic counselling, should be outlined for deal-
ing with unintentional discoveries that may confer a
health risk to the participant.
Additionally, there is a capability gap in the genetic literacy
of many current medical practitioners and the readiness of
the medical industry to provide the relevant infrastructure to
use genomics as part of usual care. Several experts have
stated that the challenges for integration of clinical genomics
into mainstream medical care include the education of pro-
viders and patients, the provisions of appropriate regulatory
framework and the accrual of sufficient evidence to draw
relevant conclusions [71]. Genetic information may be diffi-
cult to interpret for a sports medicine provider who has not
had additional training in this area [72]. The risk conferred
by gene variants differ significantly from the risk conferred
from genetic tests for Mendelian or single-gene disorders.
Genetic discoveries are often difficult to translate into
clinical practice. There are complexities in determining
which gene variants are associated with increased risk,
which have no impact on exposure to risk and whether an
increase in disease risk is clinically meaningful (e.g., from
15% to 16%). For this reason, it is important that practi-
tioners understand the impact of the testing prescribed,
and are able to provide counselling to the individual on
the risks of genetic testing or to have access to a genetic
counsellor should the need arise [71, 72].
Unsafe use of technology e.g., CRISPR-Cas9 for genetic
manipulation
The ease of accessing gene-editing techniques, such as
the CRISPR-Cas 9 technique, may make this inexpen-
sive, cut-and-paste type of gene-editing an attractive
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option for athletes wishing to use genetic performance
enhancement. Sports performance is an area where
current genetic knowledge already suggests somatic
modifications that could provide performance enhance-
ment [73]. Despite ease of access to this technology,
gene-editing remains imprecise and should only be con-
ducted by highly skilled specialists for specific medical
indications and when approved by the appropriate au-
thorities. The danger is that athletes and coaches are
seen as potential early adopters of illicit performance en-
hancing technologies [74]. There is no role for gene-
editing for the purposes of performance enhancement
and all genetic manipulations are banned under the
World Anti-Doping Agency Code [75]. Nevertheless, re-
search efforts involving state-of-the-art ‘omics’ methods
such as transcriptomics, proteomics and metabolomics
are being intensified, also by FIMS and members of the
Athlome Project Consortium, in order to identify robust
molecular signatures of doping that have particular rele-
vance in detecting gene-editing manipulations.
The way forward
International collaborations and utilising high throughput
sequencing technologies to identify genes that contribute
to exercise response
The challenge continues to be that it is difficult for one
organisation to gather sufficiently high numbers of sam-
ples to provide meaningful analysis with clinical predict-
ive value. The solution is large-scale multi-centre
collaborations to drive research in this area and to en-
sure appropriate cohort size and homogeneity.
The cost of these rapidly improving sequencing tech-
niques has been significantly reduced in the last decade.
While the first human genome took $2.7 billion and al-
most 15 years to complete, the cost to sequence a gen-
ome has now been drastically reduced to close to $1000
(‘The $1000 genome’ era) [76]. The $1000 genome refers
to an era of predictive and personalised medicine during
which the cost of fully sequencing an individual’s gen-
ome is roughly USD $1000. This already allows scientists
to sequence hundreds of thousands of genomes and will
certainly have implications in advancing the field of ex-
ercise/injury genomics.
Two symposia were held in 2015 and 2016; the first in
Greece and the second, in Slovenia, in partnership with
the International Federation of Sports Medicine (FIMS),
to review the main findings in exercise genetics and gen-
omics and to explore promising trends and possibilities
[14]. Among the participants, many were involved in on-
going collaborative studies (e.g., GAMES, Gene SMART,
GENESIS and POWERGENE). A consensus emerged
among participants that it would be advantageous to
bring together all current studies and those recently
launched into one new large collaborative initiative,
which was subsequently named the Athlome Project
Consortium. A website for the new consortium has been
developed (www.athlomeconsortium.org), and clear
goals have been established with steps to achieve these
[14]. The intention is not for the Athlome Project Con-
sortium to provide exclusivity but rather to serve as a
model for sustainable and ethical research in sport and ex-
ercise medicine. In the few years since the launch of the
Athlome project consortium, there has been much pro-
gress, with particular highlight the stimulation of multiple
international collaborative research initiatives and joint re-
search publications such as the present series published in
BMC Genomics. The two previously mentioned GWAS in-
vestigations that involved members and cohorts associated
with the Athlome consortium [55, 56] are further examples
of encouraging outcomes to date. The main obstacle for
further sustainable growth of the Athlome project consor-
tium has been its operation during a time of sustained
global research grant ‘famine’ for expensive large-scale col-
laborative research initiatives in sport and exercise medi-
cine. More consortia and large multi-centre research
initiatives are expected to follow such as the Genotype-
Tissue Expression (GTEx) program (https://commonfund.-
nih.gov/gtex) recently launched by the NIH-USA and en-
visaged to provide valuable insights into the mechanisms
of gene regulation by studying human gene expression and
regulation in multiple tissues from healthy individuals; ex-
ploring disease-related perturbations in a variety of human
diseases; and examining sexual dimorphisms in gene ex-
pression and regulation in multiple tissues.
The usefulness of genetic testing in changing behavior
There are challenges that health and exercise profes-
sionals, along with coaches from high performance ath-
letic programs, may face that relate to compliance with
exercise or preventative health programs built on genetic
analysis. Recent studies have demonstrated that direct-
to-consumer cancer risk estimates do not appear to
affect health-related behaviors positively or negatively
[77]. Despite being informed of their relative risk for a
variety of cancers, most adults did not significantly
change their diet, exercise, advanced care planning, or
cancer screening behaviors [78]. One must ask; if adults
are unlikely to change their health behavior in relation
to a serious medical condition such as cancer, will perso-
nalised genomics be relevant in the exercise and sports-
injury space? Understanding of the various behaviors
that relate to sports injury risk and exercise prescription
is needed before the relevance of genetic testing in these
fields can be uniformly applied. Many studies have in-
vestigated the compliance or adherence to health-related
exercise programs and interventions in relation to sports
injury prevention [79–82]. In relation to elite sport, a
study involving top UEFA football elite clubs
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demonstrated that athletes’ adherence to the injury pre-
vention programs remain varied, although coach compli-
ance was rated as ‘high’ [83]. This implies that attitudes
towards intervention programs reflect the beliefs of the
individual and not necessarily that of coaches or support
staff. Collard et al. recommend that a behavioral ap-
proach and ‘intervention mapping’ is required when de-
fining a sports-injury prevention program to increase
the risk of adherence [84]. A systematic approach is re-
quired in planning health promotion strategies, under
which injury prevention and exercise prescription may
be considered [85]. In addition, any possibility of intro-
ducing genetic testing in the elite sport scenario would
need to be accompanied by education to athletes and
support staff in order to improve genetic literacy.
Conclusions
Having considered the current level of scientific know-
ledge, the opinion of the stakeholders of this joint state-
ment is that the predictive value of such tests is too low
to warrant clinical application. The risks associated with
this type of testing, including privacy issues, unintended
genetic discoveries and erroneous advice based on poor
evidence, should be mitigated with understanding of the
test limitations, management of the data produced, and
avoidance of advice that is not supported by scientific
evidence. Additionally, organisations interested in the
concept of genetic testing for exercise prescription and
injury prevention should develop and clearly articulate
the ethical framework within which that organisation is
prepared to conduct genetic testing and research. Gen-
etic testing for the purposes of exercise prescription and
injury prevention may in the future be a legitimate and
valid use of genetic information contributing health ben-
efits to individuals with a wide range of athletic ability
and injury predisposition. In order for genetic testing to
become a useful component of medical practice, inten-
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